Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd. saw a significant stock decline today, contrasting with the overall market's gains. Despite recent short-term challenges, the company has shown impressive annual growth. Key financial metrics highlight its strong market position, with solid returns and robust operating cash flow, underscoring its operational strength in the sector.

Sumitomo Pharma Co., Ltd. saw a notable increase in its stock price on April 15, 2026, reaching an intraday high of JPY 2,212.00. The company reported strong financial metrics, including a net profit of JPY 96,471 million and a return on equity of 58.26%, highlighting its effective management.

Sumitomo Pharma Co., Ltd. has shown strong stock performance, achieving a notable intraday high and impressive annual returns. The company reported robust financial metrics, including significant net profit and operating cash flow, alongside a high return on equity. Despite some year-to-date decline, recent trends indicate positive momentum.

Sumitomo Pharma Co., Ltd. has shown strong stock performance, with a notable weekly gain and impressive annual returns. The company reported robust financial metrics, including a significant net profit and healthy operating cash flow, reinforcing its position in the pharmaceuticals and biotechnology sector amidst market fluctuations.

Sumitomo Pharma Co., Ltd. has shown strong stock performance, achieving a notable intraday high and a substantial annual return. The company reported robust financial metrics, including significant operating cash flow and net profit, alongside impressive return ratios, indicating effective capital utilization and strong profitability in the pharmaceuticals sector.

Sumitomo Pharma Co., Ltd. has shown strong stock performance, gaining 7.35% on March 24, 2026, with an intraday high of JPY 1,902.50. The company reported a net profit of JPY 96,471 million and a return on equity of 58.26%, indicating solid financial health and operational efficiency.

Sumitomo Pharma Co., Ltd. experienced notable stock volatility, hitting an intraday low and reflecting a significant decline for the day. Despite recent short-term challenges, the company has shown impressive long-term growth, outperforming the Nikkei 225 over the past year, with strong financial metrics supporting its market position.

Sumitomo Pharma Co., Ltd. faced notable volatility, with a significant intraday low and a daily decline. Despite recent downturns, the company has shown strong long-term growth, outperforming the Nikkei 225. Financial metrics reveal a solid operational foundation, including high return on equity and substantial net profit.

Sumitomo Pharma Co., Ltd. has recently undergone a revision in its score, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. With a remarkable return of 222.75% over the past year and consistent growth in net sales, the company continues to demonstrate robust operational health and attractive financial metrics.

Sumitomo Pharma Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. Despite a strong annual return, the company faces profitability challenges, highlighted by a low Return on Equity and a negative EBIT to Interest ratio, indicating difficulties in managing its debt.

Sumitomo Pharma Co., Ltd. saw a notable decline in its stock price, contrasting with the modest decrease of the Japan Nikkei 225. Despite recent challenges, the company has shown strong annual performance, with significant returns and solid financial metrics, including a notable operating cash flow and return on equity.

Sumitomo Pharma Co., Ltd. has shown strong stock performance, with a notable increase on September 30, 2025. The company reported significant financial metrics, including a substantial operating cash flow and impressive half-year net sales growth. Despite some long-term challenges, its current valuation remains appealing in the pharmaceuticals sector.